Shareholders of pharma companies Biovail and Valeant voted to approve their merger, and the new company is now called Valeant Pharmaceuticals International. Valeant markets Migranal dihydroergotamine nasal spray in the US, and Biovail had been partnered with Alexza on the development of Staccato loxapine since February 2010. FDA action on the Staccato loxapine NDA is expected next month. The new company is headquartered in Mississauga, Ontario, Canada. Read the company’s press release.
Biovail and Valeant merge
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
